INC424J
Total Payments
$1.3M
Transactions
18
Doctors
3
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $1.3M | 18 | 3 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $1.3M | 18 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| PHASE 3 RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTI-CENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF RUXOLITINIB IN PATIENTS WITH COVID-19 ASSOCIATED CYTOKINE STORM (RUXCOVID) | Novartis Pharmaceuticals Corporation | $1.3M | 0 |
| RESEARCH RELATED PUBLICATIONS SUPPORT | Novartis Pharmaceuticals Corporation | $714.00 | 3 |
Top Doctors Receiving Payments for INC424J
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Seattle, WA | $1.3M | 15 |
| , M.D., M.S | Infectious Disease | Newark, NJ | $238.00 | 1 |
| , MD | Internal Medicine | Ann Arbor, MI | $238.00 | 1 |
| , MD, MPH | Infectious Disease | Seattle, WA | $238.00 | 1 |
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $1.3M
- Total Doctors 3
- Transactions 18
About INC424J
INC424J is a drug associated with $1.3M in payments to 3 healthcare providers, recorded across 18 transactions in the CMS Open Payments database. The primary manufacturer is Novartis Pharmaceuticals Corporation.
Payment data is available from 2020 to 2020. In 2020, $1.3M was paid across 18 transactions to 3 doctors.
The most common payment nature for INC424J is "Unspecified" ($1.3M, 100.0% of total).
INC424J is associated with 2 research studies, including "PHASE 3 RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTI-CENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF RUXOLITINIB IN PATIENTS WITH COVID-19 ASSOCIATED CYTOKINE STORM (RUXCOVID)" ($1.3M).